Keyphrases
Ketamine
100%
Antidepressants
100%
Nitrous Oxide
100%
NMDA Receptor Antagonist
100%
Treatment-resistant Depression
37%
Older Adults
12%
United States
12%
Depressive Symptoms
12%
Management Strategy
12%
N-methyl-D-aspartate Receptor (NMDAR)
12%
Analgesia
12%
Physical Abuse
12%
Mechanism of Action
12%
Depressed Patients
12%
General Anesthesia
12%
Drugs of Abuse
12%
Downstream Effects
12%
Intranasal
12%
Drug Monitoring
12%
N-methyl-D-aspartate Receptor Antagonist
12%
United States Food
12%
Risk Management
12%
Severely Ill
12%
Evaluation Strategy
12%
Risk Evaluation
12%
Scheduled Drugs
12%
Depressive
12%
Intravenous Ketamine
12%
Inhalational
12%
Non-competitive Inhibitor
12%
Addiction Potential
12%
NMDA-type Glutamate Receptor
12%
Low Potential
12%
Intranasal Ketamine
12%
Psychological Abuse
12%
Drug Storage
12%
Drug Enforcement Agency
12%
Dissociative Anesthetics
12%
Medical Use
12%
Ill-treatment
12%
Controlled Substances
12%
Rapid-acting Antidepressant
12%
Drug Handling
12%
Pharmacology, Toxicology and Pharmaceutical Science
Antidepressant
100%
Ketamine
100%
Nitrous Oxide
100%
N Methyl Dextro Aspartic Acid Receptor Blocking Agent
100%
Treatment Resistant Depression
37%
Esketamine
25%
Anesthetic Agent
12%
Depression
12%
Competitive Inhibitor
12%
Glutamate Receptor
12%
Risk Evaluation
12%
N Methyl Dextro Aspartic Acid
12%
Controlled Substance
12%
NMDA Receptor Antagonist
12%
Neuroscience
NMDA Receptor Antagonist
100%
Antidepressant
100%
Nitrous Oxide
100%
Ketamine
100%
Treatment-Resistant Depression
37%
Esketamine
25%
Depression
12%
Glutamate Receptor
12%
N-Methyl-D-Aspartic Acid
12%
Competitive Inhibition
12%
Crossover Study
12%
Dissociative
12%